A phase I/II trial by L'Orphelin et al. combining nivolumab with autologous TILs in metastatic melanoma showed a 75% ORR, including three prolonged complete responses, highlighting the synergy of PD-1 blockade with personalized cell therapy [19] . This evidence concerns the gene PDCD1 and metastatic melanoma.